Monopar Therapeutics Inc.
$60.56
-1.1%Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to potentially treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was incorporated in 2014 and is headquartered in Wilmette, Illinois.
At a Glance
Live SnapshotIntrinsic Alpha Methodology
Thesis Lenses
Signal
Medium confidenceValuation multiple is compressed (P/E -32.7).
Valuation inputs: P/E -32.7, earnings yield N/A, momentum -1.1%.
If multiples stay elevated while momentum fades, downside repricing risk rises.
Driver
High confidenceReturn profile is soft (ROE -0.0%, ROIC -0.0%).
Profitability stack: net margin 0.0%, ROE -0.0%, ROIC -0.0%.
Quality deterioration often appears in margins before it shows up in headline EPS.
Risk
High confidenceRisk profile is balanced but has notable pressure points to monitor.
Risk factors: liabilities/assets +2.1%, momentum -1.1%, net margin 0.0%.
Higher leverage with weak momentum and thin margins can amplify drawdown severity.
Monopar Therapeutics Inc. Market vs Earnings Trajectory
Loading price and EPS data...
Monopar Therapeutics Inc. Fair Value Envelope
No Revenue Data
MNPR has not reported any revenue values in the available annual periods.
Monopar Therapeutics Inc. Profit Bridge
Profitability Analysis
No Gross Profit Margin Data
MNPR has not reported any gross profit margin values in the available annual periods.
No Operating Profit Margin Data
MNPR has not reported any operating profit margin values in the available annual periods.
No Net Profit Margin Data
MNPR has not reported any net profit margin values in the available annual periods.
Monopar Therapeutics Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Strong cash conversion. Most reported earnings translate into actual cash flow, suggesting solid fundamentals.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Minimal working capital impact on FCF. Changes in operating assets and liabilities well-managed.
Cash Flow Quality Insight
Working capital strain: Significant cash tied up in operations. Monitor receivables collection, inventory turns, and payment terms to optimize cash conversion cycle.
Monopar Therapeutics Inc. Funding & Solvency Profile
Financial Health Analysis
Current Ratio
Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.
Debt-to-Equity Ratio
Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.
Working Capital
Strong working capital position provides significant operational flexibility and financial cushion.
Asset Composition
Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.
Financial Health Insight
Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.
Monopar Therapeutics Inc. Street Expectations Map
Wall Street analysts project that MNPR stock may rise significantly over the coming 12 months. The consensus 1-year price target stands at 110.00, with estimates ranging from a low of 105.00 to a high of 115.00.
The consensus 1-year price target stands at 110.00, with estimates ranging from a low of 105.00 to a high of 115.00.
Analyst Consensus Analysis
Upside Potential
Substantial upside potential. Analysts see significant value gap, suggesting the stock may be materially undervalued at current levels.
Analyst Agreement
High analyst agreement. Narrow target range indicates strong consensus on valuation, suggesting clear investment thesis and predictable outlook.
Analyst Conviction
Strong buy conviction: High upside with tight consensus suggests compelling investment opportunity backed by analyst confidence.
Market Sentiment Insight
Rare opportunity: Exceptional upside potential with strong analyst consensus creates a compelling setup. The combination of significant price target premium and tight agreement suggests high-conviction undervaluation that may attract institutional capital.
Monopar Therapeutics Inc. Insider Positioning
During the last 12 months, insiders have purchased $105K and sold $37.01M worth of MNPR shares, resulting in $36.91M of net selling activity.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
1.5K
104.92K
4.7K
312.50K
-208K
-$208K
6-9 Months
0
0.00
550.2K
35.00M
-35.0M
-$35.00M
9-12 Months
0
0.00
42.5K
1.70M
-1.7M
-$1.70M
Top Buyers
Vu Quan Anh
Officer: Chief Financial Officer
$105K
Top Sellers
Tactic Pharma Llc
10 Percent Owner
$35.00M
Robinson Chandler
Director, Officer: Chief Executive Officer
$672K
Starr Christopher M
Director
$672K
Tsuchimoto Kim R
Director
$356K
Klausner Arthur J
Director
$312K
Insider Activity Analysis
Net Insider Sentiment
Strong bearish signal with $36.91M net selling. Heavy insider selling may indicate concerns about valuation or near-term prospects.
Buy/Sell Ratio
Very poor ratio. Heavy selling with minimal buying suggests insiders may be concerned about valuation or outlook.
Insider Participation
5 insider sellers vs. 1 buyers. Widespread selling across multiple insiders may signal concerns.
No Dividend Yield Data
MNPR has not reported any dividend yield values in the available annual periods.
mnpr Dividend History
Learning Layer
Related Guides
Build conviction on MNPR by pairing this stock hub with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.